Prakt. lékáren. 2022; 18(4): 204-207 | DOI: 10.36290/lek.2022.043

Tafamidis

Renáta Aiglová, Miloš Táborský
I. interní klinika - kardiologická, Fakultní nemocnice Olomouc

Tafamidis, a selective transthyretin stabilizer, is a novel specific therapy for transthyretin amyloidosis. This multisystemic disease is burdened by variable manifestations and a relatively unfavorable prognosis. Tafamidis is currently indicated according to guidelines for the treatment of patients with TTR-cardiomyopathy in NYHA functional class I and II to reduce symptoms, hospitalizations for cardiovascular causes and mortality.

Keywords: cardiomyopathy, heart failure, neuropathy, tafamidis, transthyretin, transthyretin­‑amyloidosis.

Accepted: December 1, 2022; Published: December 15, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Aiglová R, Táborský M. Tafamidis. Praktické lékárenství. 2022;18(4):204-207. doi: 10.36290/lek.2022.043.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286. Go to original source... Go to PubMed...
    2. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2017;39(30):2799-2806. Go to original source... Go to PubMed...
    3. Mathew V, Olson LJ, Gertz MA, Hayes DL. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol. 1997;80:1491. Go to original source... Go to PubMed...
    4. Sekijima Y, Uchiyama S, Tojo K, et al. High prevalence of wild­‑type transthyretin deposition in patienty with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011;42:1785. Go to original source... Go to PubMed...
    5. Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19:34-36. Go to original source... Go to PubMed...
    6. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007. Go to original source... Go to PubMed...
    7. Coats, Maria G Crespo­‑Leiro, Dimitrios Farmakis, Martine Gilard, Stephane Heymans, Arno W Hoes, Tiny Jaarsma, Ewa A Jankowska, Mitja Lainscak, Carolyn S P Lam, Alexander R Lyon, John J V McMurray, Alexandre Mebazaa, Richard Mindham, Claudio Muneretto, Massimo Francesco Piepoli, Susanna Price, Giuseppe M C Rosano, Frank Ruschitzka, Anne Kathrine Skibelund, ESC Scientific Document Group, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726, https://doi.org/10.1093/eurheartj/ehab368 Go to original source... Go to PubMed...
    8. Souhrn údajů o přípravku, EU/1/11/717/003-004, 6. 12. 2021. Go to original source...
    9. Aiglová R, Táborský M, Lazárová M, et al. Srdeční transthyretinová amyloidóza - častější, než jsme si mysleli? Cor et Vasa. 2017;59(4):476.
    10. Aiglová R, Táborský M.Srdeční amyloidóza - klinická manifestace a diagnostika. Medicína po promoci. 2020;2:146-150.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.